Positive Regulatory Developments and Stellar Growth for ImmunityBio

ImmunityBio has laid the groundwork for significant commercial expansion, buoyed by constructive dialogue with U.S. regulators and explosive revenue growth projected for 2025. The biotechnology firm is navigating a clear regulatory pathway for a key drug while reporting a sevenfold increase in annual sales.

Preliminary figures for the full year 2025 highlight a period of remarkable commercial traction for ImmunityBio. The company anticipates net revenue of approximately $113 million, representing a staggering 700% increase compared to the prior year. The fourth quarter alone saw $38.3 million in sales, a sequential increase of 20% and a year-over-year surge of 431%.

Supporting this revenue jump, the volume of ANKTIVA sold grew by roughly 750% in 2025. The company ended the period with a strong liquidity position, holding an estimated $243 million in cash, cash equivalents, and marketable securities.

Streamlined Path to Expanded Drug Approval

A significant development centers on the company's lead therapy, ANKTIVA. ImmunityBio has engaged in intensive discussions with the U.S. Food and Drug Administration (FDA), which have yielded a clear roadmap for resubmitting the application to expand the drug's label.

Should investors sell immediately? Or is it worth buying ImmunityBio?

Crucially, the regulatory agency has indicated that no new clinical trials will be required. Instead, the FDA has requested supplemental information to support the application for using ANKTIVA in combination with BCG for bladder cancer patients who are unresponsive to standard therapy. The company plans to submit this additional data within one month.

ANKTIVA is already approved for certain forms of non-muscle invasive bladder cancer. An extension of its indication would substantially enlarge its addressable market.

Pipeline Progress and Capital Structure Adjustment

Beyond its lead asset, ImmunityBio continues to advance its clinical pipeline. In a Phase 2 trial for recurrent glioblastoma, the median overall survival has not yet been reached. Researchers view this as a potential signal that patients may be living longer than initially anticipated.

On the financial front, the company has modified the terms of a $505 million convertible note. The adjustment allows the creditor to convert any portion of the principal amount into common shares at any time prior to maturity. This move enhances financial flexibility but introduces potential dilution pressure for existing shareholders.